NCT07308561

Brief Summary

Infertility affects approximately one in six individuals worldwide and is associated with significant psychological distress, particularly among women undergoing treatment. Increased anxiety levels are strongly linked to reduced quality of life during the infertility process. With the growing integration of artificial intelligence (AI) into healthcare, AI-based tools are increasingly used in infertility care to support decision-making and patient engagement. While many patients are familiar with AI technologies, individual attitudes toward AI may influence their acceptance and potential psychosocial benefits. This study aims to examine the relationship between attitudes toward artificial intelligence, anxiety levels, and quality of life among women undergoing infertility treatment.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
191

participants targeted

Target at P50-P75 for all trials

Timeline
5mo left

Started Oct 2025

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress54%
Oct 2025Oct 2026

Study Start

First participant enrolled

October 23, 2025

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

December 17, 2025

Completed
12 days until next milestone

First Posted

Study publicly available on registry

December 29, 2025

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 23, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 23, 2026

Last Updated

December 29, 2025

Status Verified

December 1, 2025

Enrollment Period

1 year

First QC Date

December 17, 2025

Last Update Submit

December 17, 2025

Conditions

Outcome Measures

Primary Outcomes (4)

  • Sociodemographic and Descriptive Information Form

    This form includes 30 items designed to collect data on participants' sociodemographic characteristics, general health status, obstetric and gynecological history, and use of technology and artificial intelligence. It provides a comprehensive background profile of women undergoing infertility treatment.

    At baseline (one-time assessment at enrollment)

  • State-Trait Anxiety Inventory (STAI) - Trait Anxiety Scale

    The Trait Anxiety Scale is used to assess individuals' general and persistent anxiety levels. The scale consists of multiple items rated on a Likert-type format, with total scores ranging from 20 to 80. Higher scores indicate higher levels of anxiety.

    At baseline (one-time assessment at enrollment)

  • General Attitudes Toward Artificial Intelligence Scale

    This scale assesses individuals' positive and negative attitudes toward artificial intelligence using a 5-point Likert-type format. It consists of 20 items, with negatively worded items reverse-coded. Higher total scores reflect more positive attitudes toward artificial intelligence.

    At baseline (one-time assessment at enrollment)

  • Fertility Quality of Life Scale (FertiQol) - Core Module

    The Fertility Quality of Life Scale evaluates quality of life in individuals experiencing fertility problems. The core module assesses emotional, mind-body, relational, and social dimensions of quality of life using a Likert-type response format. Higher scores indicate better quality of life.

    At baseline (one-time assessment at enrollment)

Eligibility Criteria

Age18 Years - 45 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Women aged 18-45 years diagnosed with primary or secondary infertility and currently undergoing infertility treatment (IUI, IVF, or ICSI).

You may qualify if:

  • Women aged 18-45 years diagnosed with infertility (primary or secondary infertility).
  • Women undergoing infertility treatment and those who have experienced various treatment modalities (IUI, IVF, ICSI).
  • Women who voluntarily agree to participate in the study.
  • Women who are able to understand and speak Turkish.

You may not qualify if:

  • Women with diagnosed psychological disorders (e.g., clinical depression, anxiety disorders).
  • Women who are not undergoing infertility treatment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Acıbadem Health Group

Istanbul, Ataşehir, Turkey (Türkiye)

RECRUITING

Related Publications (16)

  • European Society of Human Reproduction and Embryology (ESHRE). (2024, April). Factsheet on infertility - prevalence, treatment and fertility decline in Europe. ESHRE. https://www.eshre.eu

    BACKGROUND
  • Shi Z, Zheng Y, Zhu X, Mao Z, Nie H, Chen G, Li S. Understanding health-related quality of life in Chinese infertility patients: a qualitative study. Qual Life Res. 2025 Nov;34(11):3105-3119. doi: 10.1007/s11136-025-04066-y. Epub 2025 Sep 13.

    PMID: 40944797BACKGROUND
  • Simionescu G, Doroftei B, Maftei R, Obreja BE, Anton E, Grab D, Ilea C, Anton C. The complex relationship between infertility and psychological distress (Review). Exp Ther Med. 2021 Apr;21(4):306. doi: 10.3892/etm.2021.9737. Epub 2021 Feb 1.

    PMID: 33717249BACKGROUND
  • Song D, Li X, Yang M, Wang N, Zhao Y, Diao S, Zhang X, Gou X, Zhu X. Fertility quality of life (FertiQoL) among Chinese women undergoing frozen embryo transfer. BMC Womens Health. 2021 Apr 24;21(1):177. doi: 10.1186/s12905-021-01325-1.

    PMID: 33894750BACKGROUND
  • Gameiro S, Boivin J, Dancet E, de Klerk C, Emery M, Lewis-Jones C, Thorn P, Van den Broeck U, Venetis C, Verhaak CM, Wischmann T, Vermeulen N. ESHRE guideline: routine psychosocial care in infertility and medically assisted reproduction-a guide for fertility staff. Hum Reprod. 2015 Nov;30(11):2476-85. doi: 10.1093/humrep/dev177. Epub 2015 Sep 7.

    PMID: 26345684BACKGROUND
  • Cromack SC, Lew AM, Bazzetta SE, Xu S, Walter JR. The perception of artificial intelligence and infertility care among patients undergoing fertility treatment. J Assist Reprod Genet. 2025 Mar;42(3):855-863. doi: 10.1007/s10815-024-03382-5. Epub 2025 Jan 7.

    PMID: 39776390BACKGROUND
  • Medenica S, Zivanovic D, Batkoska L, Marinelli S, Basile G, Perino A, Cucinella G, Gullo G, Zaami S. The Future Is Coming: Artificial Intelligence in the Treatment of Infertility Could Improve Assisted Reproduction Outcomes-The Value of Regulatory Frameworks. Diagnostics (Basel). 2022 Nov 28;12(12):2979. doi: 10.3390/diagnostics12122979.

    PMID: 36552986BACKGROUND
  • Sarshoori, A. A., Mostafavi, M., Heidarpoor, S., & Chekeni, A. M. (2024). Role of Artificial Intelligence in Infertility Screening and Treatment: A Systematic Review. Iranian Biomedical Journal, 28, 253.

    BACKGROUND
  • Lee, C., Chae, H. J., Kim, H. M., Lee, H., Choi, S., & Min, H. S. (2024). Enhancing infertility care with a ChatGPT-based chatbot: integrating clinical and community insights for improved patient support. Fertility and Sterility, 122(4), e141-e142.

    BACKGROUND
  • Méndez-Suárez, M., Delbello, L., de Vega de Unceta, A., & Ortega Larrea, A. L. (2024). Factors affecting consumers' attitudes towards artificial intelligence. Journal of Promotion Management, 30(7), 1141-1158.

    BACKGROUND
  • Mendizabal-Ruiz G, Paredes O, Borrayo E, Chavez-Badiola A. FERTILITY CARE IN LOW- AND MIDDLE- INCOME COUNTRIES: The future use of AI to improve accessibility of assisted reproductive technology in low- and middle-income countries. Reprod Fertil. 2025 Aug 14;6(3):e240077. doi: 10.1530/RAF-24-0077. Print 2025 Jul 1.

    PMID: 40736784BACKGROUND
  • Massarotti C, Gentile G, Ferreccio C, Scaruffi P, Remorgida V, Anserini P. Impact of infertility and infertility treatments on quality of life and levels of anxiety and depression in women undergoing in vitro fertilization. Gynecol Endocrinol. 2019 Jun;35(6):485-489. doi: 10.1080/09513590.2018.1540575. Epub 2019 Jan 7.

    PMID: 30612477BACKGROUND
  • Braverman AM, Davoudian T, Levin IK, Bocage A, Wodoslawsky S. Depression, anxiety, quality of life, and infertility: a global lens on the last decade of research. Fertil Steril. 2024 Mar;121(3):379-383. doi: 10.1016/j.fertnstert.2024.01.013. Epub 2024 Jan 13.

    PMID: 38224730BACKGROUND
  • Kaya, F., Aydin, F., Schepman, A., Rodway, P., Yetişensoy, O., & Demir Kaya, M. (2022). The roles of personality traits, AI anxiety, and demographic factors in attitudes towards artificial intelligence. International Journal of Human-Computer Interaction. https://doi.org/10.1080/10447318.2022.2151730

    BACKGROUND
  • Schepman A, Rodway P. Initial validation of the general attitudes towards Artificial Intelligence Scale. Comput Hum Behav Rep. 2020 Jan-Jul;1:100014. doi: 10.1016/j.chbr.2020.100014. Epub 2020 May 18.

    PMID: 34235291BACKGROUND
  • Schepman, A. & Rodway, P. (2022). The General Attitudes towards Artificial Intelligence Scale (GAAIS): Confirmatory Validation and Associations with Personality, Corporate Distrust, and General Trust. International Journal of Human-Computer Interaction https://doi.org/10.1080/10447318.2022.2085400

    BACKGROUND

MeSH Terms

Conditions

Infertility, FemaleAnxiety Disorders

Condition Hierarchy (Ancestors)

Genital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital DiseasesInfertilityMental Disorders

Central Study Contacts

Güzin Ünlü Suvari, M.Sc.

CONTACT

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
M.Sc., Lecturer

Study Record Dates

First Submitted

December 17, 2025

First Posted

December 29, 2025

Study Start

October 23, 2025

Primary Completion (Estimated)

October 23, 2026

Study Completion (Estimated)

October 23, 2026

Last Updated

December 29, 2025

Record last verified: 2025-12

Data Sharing

IPD Sharing
Will not share

Individual participant data (IPD) will not be publicly shared due to privacy concerns and the sensitive nature of maternal and infant health information. However, anonymized data may be made available upon reasonable request to the corresponding author after publication of the study results.

Locations